Shapiro GI - Search Results

1

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Engstrom LD, et al. Among authors: shapiro gi. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765324 Clinical Trial.

2

Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.

Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ. Shapiro GI, et al. Cancer Res. 1995 Feb 1;55(3):505-9. Cancer Res. 1995. PMID: 7834618

3

Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.

Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ. Shapiro GI, et al. Cancer Res. 1995 Dec 15;55(24):6200-9. Cancer Res. 1995. PMID: 8521414

4

Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.

Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Shapiro GI, et al. Clin Cancer Res. 1999 Oct;5(10):2925-38. Clin Cancer Res. 1999. PMID: 10537362

5

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ. Shapiro GI, et al. Clin Cancer Res. 2001 Jun;7(6):1590-9. Clin Cancer Res. 2001. PMID: 11410495 Clinical Trial.

6

A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ. Fidias P, et al. Clin Cancer Res. 2001 Dec;7(12):3942-9. Clin Cancer Res. 2001. PMID: 11751486 Clinical Trial.

7

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Maulik G, et al. Among authors: shapiro gi. Clin Cancer Res. 2002 Feb;8(2):620-7. Clin Cancer Res. 2002. PMID: 11839685

8

Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.

Matranga CB, Shapiro GI. Matranga CB, et al. Among authors: shapiro gi. Cancer Res. 2002 Mar 15;62(6):1707-17. Cancer Res. 2002. PMID: 11912144

9

Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.

Jiang J, Matranga CB, Cai D, Latham VM Jr, Zhang X, Lowell AM, Martelli F, Shapiro GI. Jiang J, et al. Among authors: shapiro gi. Cancer Res. 2003 Nov 1;63(21):7410-22. Cancer Res. 2003. PMID: 14612540

10

Novel agents in the treatment of lung cancer: conference summary statement.

Lynch TJ, Adjei AA, Bunn PA Jr, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Lynch TJ, et al. Among authors: shapiro gi. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4199s-4204s. doi: 10.1158/1078-0432.CCR-040021. Clin Cancer Res. 2004. PMID: 15217958 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters